COMMD8 changes expression during initial phase of wasp venom immunotherapy.
Adolescent
Adult
Aged
Animals
Biomarkers
/ metabolism
Case-Control Studies
Delta-5 Fatty Acid Desaturase
Desensitization, Immunologic
/ methods
Female
Gene Expression Profiling
Humans
Hymenoptera
/ immunology
Hypersensitivity, Immediate
/ etiology
Immunoglobulin E
/ immunology
Insect Bites and Stings
/ complications
Male
Middle Aged
Prognosis
Skin Tests
Wasp Venoms
/ therapeutic use
Wasps
/ immunology
Young Adult
RNA
allergy
gene expression
immune response
Journal
The journal of gene medicine
ISSN: 1521-2254
Titre abrégé: J Gene Med
Pays: England
ID NLM: 9815764
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
17
01
2020
revised:
02
04
2020
accepted:
10
06
2020
pubmed:
20
6
2020
medline:
1
9
2021
entrez:
20
6
2020
Statut:
ppublish
Résumé
Hymenoptera venom allergy (HVA) is of great concern because of the possibility of anaphylaxis, which may be fatal. Venom immunotherapy (VIT) is the only disease-modifying treatment in HVA and, although efficient, its mechanism remains partially unknown. Gene expression analysis may be helpful for establishing a proper model of tolerance induction during the build-up phase of VIT. The present study aimed to analyze how the start of VIT changes the expression of 15 selected genes. Forty-five patients starting VIT with a wasp venom allergy were enrolled. The diagnosis was established based on anaphylaxis history (third or fourth grade on the Mueller scale) and positive soluble immunoglobulin E and/or skin tests. Two blood collections were performed in the patient group: before and after 3 months of VIT. One sample was taken in the control group. Gene expression analysis was performed using a reverse transcriptase-polymerase chain reaction with microfluidic cards and normalized to the 18S housekeeping gene. Commd8 was the only gene that changed expression significantly after the start of VIT (p = 0.012). Its expression decreased towards the levels observed in the healthy controls. Twelve out of 15 genes (commd8, cldn1, cngb3, fads1, hes6, hla-drb5, htr3b, prlr, slc16a4, snx33, socs3 and twist2) revealed a significantly different expression compared to the healthy controls. The present study shows that commd8 changes significantly its expression during initial phase of VIT. This gene might be a candidate for VIT biomarker in future studies.
Sections du résumé
BACKGROUND
Hymenoptera venom allergy (HVA) is of great concern because of the possibility of anaphylaxis, which may be fatal. Venom immunotherapy (VIT) is the only disease-modifying treatment in HVA and, although efficient, its mechanism remains partially unknown. Gene expression analysis may be helpful for establishing a proper model of tolerance induction during the build-up phase of VIT. The present study aimed to analyze how the start of VIT changes the expression of 15 selected genes.
METHODS
Forty-five patients starting VIT with a wasp venom allergy were enrolled. The diagnosis was established based on anaphylaxis history (third or fourth grade on the Mueller scale) and positive soluble immunoglobulin E and/or skin tests. Two blood collections were performed in the patient group: before and after 3 months of VIT. One sample was taken in the control group. Gene expression analysis was performed using a reverse transcriptase-polymerase chain reaction with microfluidic cards and normalized to the 18S housekeeping gene.
RESULTS
Commd8 was the only gene that changed expression significantly after the start of VIT (p = 0.012). Its expression decreased towards the levels observed in the healthy controls. Twelve out of 15 genes (commd8, cldn1, cngb3, fads1, hes6, hla-drb5, htr3b, prlr, slc16a4, snx33, socs3 and twist2) revealed a significantly different expression compared to the healthy controls.
CONCLUSIONS
The present study shows that commd8 changes significantly its expression during initial phase of VIT. This gene might be a candidate for VIT biomarker in future studies.
Substances chimiques
Biomarkers
0
Delta-5 Fatty Acid Desaturase
0
Wasp Venoms
0
Immunoglobulin E
37341-29-0
FADS1 protein, human
EC 1.14.19.3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3243Informations de copyright
© 2020 John Wiley & Sons, Ltd.
Références
Bilo BM, Bonifazi F. Epidemiology of insect-venom anaphylaxis. Curr Opin Allergy Clin Immunol. 2008;8:330-337.
Tejedor Alonso MA, Moro Moro M, Múgica García MV. Epidemiology of anaphylaxis. Clin Exp Allergy. 2015;45:1027-1039.
Schwartz HJ, Squillace DL, Sher TH, Teigland JD, Yunginger JW. Studies in stinging insect hypersensitivity: postmortem demonstration of antivenom IgE antibody in possible sting-related sudden death. Am J Clin Pathol. 1986;85:607-610.
Nittner-Marszalska M, Liebhart J, Liebhart E, et al. Prevalence of hymenoptera venom allergy and its immunological markers current in adults in Poland. Med Sci Monit. 2004;10:CR324-CR329.
Bilo MB, Pravettoni V, Bignardi D, et al. Hymenoptera venom allergy: Management of Children and Adults in clinical practice. J Investig Allergol Clin Immunol. 2019;29:180-205.
Sturm GJ, Varga E-M, Roberts G, et al. EAACI guidelines on allergen immunotherapy: hymenoptera venom allergy. Allergy. 2018;73:744-764.
Boyle RJ, Elremeli M, Hockenhull J, et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev. 2012;10:CD008838. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008838.pub2/full
Global Atlas of Allergy - EAACI. C. Akdis ed. Zurich Switzerland: European Academy of Allergy and Clinical Immunology.
Cavkaytar O, Akdis CA, Akdis M. Modulation of immune responses by immunotherapy in allergic diseases. Curr Opin Pharmacol. 2014;17:30-37.
Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J. 2015;8(1):1-12.
Ozdemir C, Kucuksezer UC, Akdis M, Akdis CA. Mechanisms of immunotherapy to wasp and bee venom. Clin Exp Allergy. 2011;41:1226-1234.
Stone SF, Brown SGA. Mediators released during human anaphylaxis. Curr Allergy Asthma Rep. 2012;12:33-41.
Stone SF, Bosco A, Jones A, et al. Genomic responses during acute human anaphylaxis are characterized by upregulation of innate inflammatory gene networks. PLoS ONE. 2014;9:(7):1-12, e101409.
Carmona-Saez P, Chagoyen M, Tirado F, Carazo JM, Pascual-Montano A. GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists. Genome Biol. 2007;8:1-8, R3.
Nogales-Cadenas R, Carmona-Saez P, Vazquez M, et al. GeneCodis: interpreting gene lists through enrichment analysis and integration of diverse biological information. Nucleic Acids Res. 2009;37:W317-W322.
Tabas-Madrid D, Nogales-Cadenas R, Pascual-Montano A. GeneCodis3: a non-redundant and modular enrichment analysis tool for functional genomics. Nucleic Acids Res. 2012;40:W478-W483.
Niedoszytko M, Bruinenberg M, de Monchy J, et al. Gene expression analysis in predicting the effectiveness of insect venom immunotherapy. J Allergy Clin Immunol. 2010;125:1092-1097.
Niedoszytko M, Bruinenberg M, de Monchy J, et al. Changes in gene expression caused by insect venom immunotherapy responsible for the long-term protection of insect venom-allergic patients. Ann Allergy Asthma Immunol. 2011;106:502-510.
Bilo BM, Rueff F, Mosbech H, Bonifazi F, Oude Elberink JN. Hypersensitivity EIG on IV. Diagnosis of hymenoptera venom allergy. Allergy. 2005;60:1339-1349.
Patella V, Florio G, Giuliano A, et al. Hymenoptera venom immunotherapy: tolerance and efficacy of an Ultrarush protocol versus a rush and a slow conventional protocol. J Allergy. 2012;2012:192192-192198.
Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611-622.
UR M. Clinical Presentation and Pathogenesis. Insect sting allergy. Stuggart: Gustav Fischer; 1990.33-65.
Burstein E, Hoberg JE, Wilkinson AS, et al. COMMD proteins, a novel family of structural and functional homologs of MURR1. J Biol Chem. 2005;280:22222-22232.
McDonald FJ, Biasio W, Chang T, et al. COMMD1 and ion transport proteins: what is the COMMection? Focus on "COMMD1 interacts with the COOH terminus of NKCC1 in Calu-3 airway epithelial cells to modulate NKCC1 ubiquitination". Am J Physiol Cell Physiol. 2013;305:C129-C130.
Chang T, Ke Y, Ly K, McDonald FJ. COMMD1 regulates the delta epithelial sodium channel (δENaC) through trafficking and ubiquitination. Biochem Biophys Res Commun. 2011;411:506-511.
van de Sluis B, Muller P, Duran K, et al. Increased activity of hypoxia-inducible factor 1 is associated with early embryonic lethality in Commd1 null mice. Mol Cell Biol. 2007;27:4142-4156.
Maine GN, Mao X, Muller PA, Komarck CM, Klomp LWJ, Burstein E. COMMD1 expression is controlled by critical residues that determine XIAP binding. Biochem J. 2009;417:601-609.
Starokadomskyy P, Gluck N, Li H, et al. CCDC22 deficiency in humans blunts activation of proinflammatory NF-kappaB signaling. J Clin Invest. 2013;123:2244-2256.
Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008;132:344-362.
Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest. 2001;107:7-11.
La Grutta S, Gagliardo R, Mirabella F, et al. Clinical and biological heterogeneity in children with moderate asthma. Am J Respir Crit Care Med. 2003;167:1490-1495.
Taher YA, van Esch BCAM, Hofman GA, Henricks PAJ, van Oosterhout AJM. 1,25-Dihydroxyvitamin D3 potentiates the beneficial effects of allergen immunotherapy in a mouse model of allergic asthma: role for IL-10 and TGF. J Immunol. 2008;180:5211-5221.
Yoo S, Ha S-J. Generation of Tolerogenic dendritic cells and their therapeutic applications. Immune Netw. 2016;16:52-60.
Gerondakis S, Fulford TS, Messina NL, Grumont RJ. NF-kappaB control of T cell development. Nat Immunol. 2014;15:15-25.
Lu Y, Hippen KL, Lemire AL, et al. miR-146b antagomir treated human Tregs increase TRAF6-NFkB expression, suppressor function and GVHD inhibitory potency. Blood. 128:1424-1435.
Nakai A, Fujimoto J, Miyata H, et al. The COMMD3/8 complex determines GRK6 specificity for chemoattractant receptors. J Exp Med. 2019;216:1630-1647.
Li G, Liu Z, Zhong N, Liao B, Xiong Y. Therapeutic effects of DNA vaccine on allergen-induced allergic airway inflammation in mouse model. Cell Mol Immunol. 2006;3:379-384.
Tsai Y-G, Chiou Y-L, Chien J-W, Wu H-P, Lin C-Y. Induction of IL-10+ CD4+ CD25+ regulatory T cells with decreased NF-κB expression during immunotherapy. Pediatr Allergy Immunol. 2010;21:e166-e173.
Ventura I, Vega A, Chamorro C, et al. Allergen immunotherapy decreases LPS-induced NF-κB activation in neutrophils from allergic patients. Pediatr Allergy Immunol. 2014;25:129-135.
Kritas SK, Saggini A, Cerulli G, et al. Relationship between serotonin and mast cells: inhibitory effect of anti-serotonin. J Biol Regul Homeost Agents. 28:377-380.
Kushnir-Sukhov NM, Brittain E, Scott L, Metcalfe DD. Clinical correlates of blood serotonin levels in patients with mastocytosis. Eur J Clin Invest. 2008;38:953-958.
Vamey VA, Hamid QA, Gaga M, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest. 1993;92:644-651.
Zhang C, Nygaard M, Haxholm GW, et al. A residue quartet in the extracellular domain of the prolactin receptor selectively controls mitogen-activated protein kinase signaling. J Biol Chem. 2015;290:11890-11904.
Akdis M, Aab A, Altunbulakli C, et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2016;138:984-1010.
Wu M, Chen X, Lou J, et al. TGF-β1 contributes to CD8+ Treg induction through p38 MAPK signaling in ovarian cancer microenvironment. Oncotarget. 7:44534-44544.
Garaud S, Taher TE, Debant M, et al. CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes. Cell Mol Immunol. 2016;15:158-170.
Ramírez de Arellano A, Lopez-Pulido EI, Martínez-Neri PA, et al. STAT3 activation is required for the antiapoptotic effects of prolactin in cervical cancer cells. Cancer Cell Int. 2015;15:1-8, 83.
Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAK-Stat. 2013;2:1-9, e24137.
Mogensen TH. STAT3 and the hyper-IgE syndrome: clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties. JAK-Stat. 2013;2:1-9, e23435.
Wang W-B, Levy DE, Lee C-K. STAT3 negatively regulates type I IFN-mediated antiviral response. J Immunol. 2011;187:2578-2585.
Yin Y, Liu W, Dai Y. SOCS3 and its role in associated diseases. Hum Immunol. 2015;76:775-780.
Chaves De Souza JA, Nogueira AVB, Chaves De Souza PP, et al. SOCS3 expression correlates with severity of inflammation, expression of proinflammatory cytokines, and activation of STAT3 and p38 MAPK in LPS-induced inflammation in vivo. Mediators Inflamm. 2013;2013:1-10.
Shiozaki A, Shimizu H, Ichikawa D, et al. Claudin 1 mediates tumor necrosis factor alpha-induced cell migration in human gastric cancer cells. World J Gastroenterol. 2014;20:17863-17876.
Samuvel DJ, Sundararaj KP, Nareika A, Lopes-Virella MF, Huang Y. Lactate boosts TLR4 signaling and NF-kappaB pathway-mediated gene transcription in macrophages via monocarboxylate transporters and MD-2 up-regulation. J Immunol. 2009;182:2476-2484.
Siebenhaar F, Magerl M, Peters EMJ, Hendrix S, Metz M, Maurer M. Mast cell-driven skin inflammation is impaired in the absence of sensory nerves. J Allergy Clin Immunol. 2008;121:955-961.